Compugen Ltd. (CGEN)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

6.14-0.41 (-6.26%)

At close: 4:00PM EDT

6.19 +0.05 (+0.81%)
After hours: 04:34PM EDT

Advertisement

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bullishpattern detected

Momentum

View all chart patterns

Performance Outlook

Previous Close	6.55
Open	6.48
Bid	6.02 x 1800
Ask	6.16 x 2900
Day's Range	6.06 - 6.50
52 Week Range	5.76 - 15.16
Volume	637,803
Avg. Volume	689,540

Market Cap	515.256M
Beta (5Y Monthly)	2.32
PE Ratio (TTM)	N/A
EPS (TTM)	-0.43
Earnings Date	Nov 03, 2021 - Nov 08, 2021
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	N/A

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for CGEN

Learn more

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

Compugen Ltd.
Analyst Report: Abbott LaboratoriesAbbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Rating
Fair Value
Economic Moat
2 days agoMorningstar

All

News

Press Releases

Research Reports

PR Newswire
Compugen Announces Milestone Payment from AstraZeneca Triggered by First Patient Dosed with TIGIT Bispecific Derived from COM902
Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that Compugen is entitled to receive a $6 million milestone payment from AstraZeneca (LSE: AZN) (STO: AZN) (Nasdaq: AZN) triggered by the dosing of the first patient in a Phase 1/2 study evaluating AZD2936, a TIGIT/PD-1 bispecific antibody, in patients with advanced or metastatic non-small cell lung cancer. AZD2936 is derived from COM902, Compugen's high-affini
PR Newswire
Compugen To Present Clinical Data from anti-TIGIT COM902 Monotherapy and Triple Combination Dose Escalation Studies at SITC 2021
Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that new clinical and preclinical data will be presented at the 36th Annual Meeting of the Society for Immunotherapy of Cancer, which will be held on November 10-14, 2021.
PR Newswire
Compugen to Present at the Cantor Global Healthcare Conference
Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced that management will present at the Cantor Global Healthcare Conference on Thursday, September 30, 2021 at 1:20 pm ET.